American Journal of Psychiatry
Fecha de publicación: 1 August 2020
DOI: https://doi.org/10.1176/appi.ajp.2020.20060844
Autores: Linda L. Carpenter, M.D., Noah S. Philip, M.D.
Background: While brain stimulation with magnetic fields may still seem like a “new” approach to many clinicians, more than a decade has passed since the first transcranial magnetic stimulation (TMS) device for treating major depressive disorder received regulatory approval from the U.S. Food and Drug Administration.
